Key Highlights

  • Anteris Technologies Global opened at $7.97 on Friday, up from a prior close of $7.61, after filings showed major holder L1 Capital bought 322,940 shares at $7.60 on October 1 and 74,286 shares at $7.72 on September 30.
  • Together the purchases were worth about $3.03 million and brought L1 Capital's holding to 5.2 million shares; the stock's closing price for the day could not be confirmed.
  • Anteris is developing DurAVR, a transcatheter aortic valve designed to treat aortic stenosis, delivered through a blood vessel rather than open-heart surgery, and the company has a Market Value of about $773 million.
  • Health care lagged the wider market on Friday, the only one of the eleven S&P 500 sectors to close lower, with Integra LifeSciences tumbling and an FDA warning letter to Evolus also part of the sector's news.

Anteris Technologies Global (NASDAQ:AVR) opened higher after regulatory filings showed one of its large shareholders, L1 Capital, bought more shares earlier in the week. The stock gapped higher at the open on Friday, October 2, after disclosed filings showed that major holder L1 Capital had added to its position. The stock opened at $7.97, up from a prior close of $7.61. Its closing price for the day could not be confirmed. The company has a market value of about $773 million.

What the Filings Showed

L1 Capital Pty Ltd bought 322,940 shares at $7.60 each on October 1, and 74,286 shares at $7.72 each on September 30. Together, the purchases were worth about $3.03 million and brought L1 Capital's holding to 5.2 million shares.

Large shareholders are required to report trades like these, and the filings are routine disclosures. They do not on their own say anything about why a holder chose to buy, and the company did not announce any news of its own alongside them.

Still, purchases by a big existing investor tend to catch traders' attention, especially in a smaller stock. Friday's gap higher was tied to the buying activity.

What Anteris Does

Anteris is a structural heart company. It is developing DurAVR, a transcatheter aortic valve designed to treat aortic stenosis, a narrowing of the heart's main valve that becomes more common with age. Transcatheter valves are delivered through a blood vessel rather than through open-heart surgery.

Like many development-stage medical device companies, Anteris is focused on Clinical Trials and regulatory steps rather than large product revenues, which can make its shares sensitive to shifts in sentiment and funding conditions.

A Mixed Day for Health Care

Anteris's early gain came on a day when health care lagged the wider market. It was the only one of the eleven S&P 500 sectors to close lower, and it fell only barely.

The sector had its share of setbacks. Integra LifeSciences tumbled after cutting its 2026 guidance because of flooding at a Manufacturing site. The FDA published a warning letter to Evolus over a Social Media promotion for its frown-line treatment.

A Rally Led by Tech

The broader market rose after a weak September jobs report. The economy added 29,000 jobs, well short of forecasts near 84,000, and the Unemployment rate ticked up. That sent odds of another Federal Reserve rate hike in October sharply lower, after the Fed raised rates on September 16 for the first time since 2023.

The Nasdaq Composite rose 319.27 points to 27,190.86, touching an intraday all-time high without setting a record close. The Nasdaq-100 notched a record close. Chipmakers led the way, with Nvidia hitting a record high during the session.

Treasury yields fell after the jobs data but then reversed and closed higher, with the 10-year near its highest level since 2002. Higher long-term yields can weigh on development-stage companies that may need to raise capital.

Watching for Further Filings and Clinical Updates

Investors will look for any further disclosed filings from L1 Capital or other large holders, as well as clinical and regulatory updates on the DurAVR valve. Because Friday's close was not confirmed, Monday's session will show whether the gap higher held. More broadly, the Fed's October 27 to 28 meeting and the next Inflation readings will shape the backdrop for smaller medical device stocks, which often move sharply on modest volumes.